Analyst Ami Fadia of Needham maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of $133.00. Ami Fadia has given his Buy rating due to a ...

Acrivon Therapeutics, Inc. (ACRV – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Li Watsek today. The company’s shares closed yesterday at $5.79.

Outlook Therapeutics (OTLK) announced Faisal Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Sukhtian will assume the role from Randy Thurman, who will ...

Axsome Therapeutics (AXSM) will host a virtual investor event and conference call at 8:00 AM Eastern Time to discuss the U.S. Food and Drug Administration approval of SYMBRAVO, a novel multi ...

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of $125.00. Vikram Purohit’s rating is based on ...

JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target Astria is using its half-life extension technology to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics ...

Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares after the company reported Phase 2 data for lead ...

Atossa Therapeutics (ATOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on ...

“Coeptis Therapeutics (COEP) is excited to announce its rebranding to Coeptis, marking a transformative shift in its business strategy. This pivotal change reflects our commitment to expanding ...

Kazia Therapeutics (KZIA) is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast ...